idebenone has been researched along with Disease Models, Animal in 28 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, the effects of 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (idebenone) on neurological signs, such as ischemic seizures, lactate and ATP contents of the cerebral cortex, and local cerebral blood flow, were assessed in stroke-prone spontaneously hypertensive rats (SHRSP) with experimentally induced cerebral ischemia." | 7.67 | Effects of idebenone on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia. ( Kakihana, M; Nagaoka, A; Shibota, M; Suno, M, 1989) |
| "Sepsis is an uncontrolled systemic infection, withcomplex pathophysiology that may result in acute lung organ damage and cause multiple organ failure." | 5.72 | Protective Effects of Idebenone against Sepsis Induced Acute Lung Damage. ( Akpinar, E; Aydin, P; Bayraktutan, Z; Dincer, B; Eser, G; Kose, D; Kutlu, Z; Tavaci, T; Yildirim, S; Yuksel, TN, 2022) |
| "Idebenone is a coenzyme Q10 synthetic quinone analog and an antioxidant that has been used in humans to treat diverse diseases in which mitochondrial function is impaired." | 5.56 | Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone. ( Blanco, LP; Carmona-Rivera, C; Hoffmann, V; Kaplan, MJ; Lightfoot, YL; Pedersen, HL; Seto, N; Wang, X; Yu, ZX; Yuen, PST, 2020) |
| "Idebenone was co-administered orally at a dose of 200 mg/kg body weight." | 5.56 | Idebenone Protects against Acute Murine Colitis via Antioxidant and Anti-Inflammatory Mechanisms. ( Eri, R; Gueven, N; Shastri, S; Shinde, T; Sohal, SS, 2020) |
| "Pretreatment with idebenone (10 mg/kg, i." | 5.28 | Effects of idebenone on the levels of acetylcholine, choline, free fatty acids, and energy metabolites in the brains of rats with cerebral ischemia. ( Kakihana, M; Nagaoka, A; Yamazaki, N, 1989) |
| " In the present study, the effects of 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone (idebenone) on neurological signs, such as ischemic seizures, lactate and ATP contents of the cerebral cortex, and local cerebral blood flow, were assessed in stroke-prone spontaneously hypertensive rats (SHRSP) with experimentally induced cerebral ischemia." | 3.67 | Effects of idebenone on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia. ( Kakihana, M; Nagaoka, A; Shibota, M; Suno, M, 1989) |
| "Sepsis is an uncontrolled systemic infection, withcomplex pathophysiology that may result in acute lung organ damage and cause multiple organ failure." | 1.72 | Protective Effects of Idebenone against Sepsis Induced Acute Lung Damage. ( Akpinar, E; Aydin, P; Bayraktutan, Z; Dincer, B; Eser, G; Kose, D; Kutlu, Z; Tavaci, T; Yildirim, S; Yuksel, TN, 2022) |
| "Idebenone (IDB) has demonstrated the potential to treat mitochondrial and neurodegenerative diseases, including Alzheimer's disease (AD)." | 1.62 | Effectiveness of idebenone nanorod formulations in the treatment of Alzheimer's disease. ( Fu, Q; Guo, M; He, Z; Huang, Y; Li, M; Liu, P; Ma, M; Zhu, X, 2021) |
| "Idebenone was recently identified as the first small-molecule Shc inhibitor drug." | 1.62 | Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice. ( Cortopassi, G; Hui, CK; Jiang, JX; Montgomery, C; Tomilov, A; Török, NJ, 2021) |
| "Idebenone is a coenzyme Q10 synthetic quinone analog and an antioxidant that has been used in humans to treat diverse diseases in which mitochondrial function is impaired." | 1.56 | Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone. ( Blanco, LP; Carmona-Rivera, C; Hoffmann, V; Kaplan, MJ; Lightfoot, YL; Pedersen, HL; Seto, N; Wang, X; Yu, ZX; Yuen, PST, 2020) |
| "Idebenone was co-administered orally at a dose of 200 mg/kg body weight." | 1.56 | Idebenone Protects against Acute Murine Colitis via Antioxidant and Anti-Inflammatory Mechanisms. ( Eri, R; Gueven, N; Shastri, S; Shinde, T; Sohal, SS, 2020) |
| "This study investigates the effect of insulin combined with idebenone on blood-brain barrier (BBB) permeability in experimental streptozotocin-induced diabetic rats as well as the underlying mechanisms." | 1.42 | Effects of insulin combined with idebenone on blood-brain barrier permeability in diabetic rats. ( Liu, LB; Sun, YN; Wang, P; Xue, YX, 2015) |
| "However, in experimental autoimmune encephalomyelitis, idebenone failed to affect disease incidence or onset when applied preventively, or to reduce disease severity when applied therapeutically." | 1.39 | The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. ( Bros, H; Chanvillard, C; Dörr, J; Fiebiger, SM; Grobosch, T; Infante-Duarte, C; Janssen, A; Millward, JM; Paul, F, 2013) |
| " Consistent with the reported dosing and observed effects in LHON patients, we describe that in mice, idebenone penetrated into the eye at concentrations equivalent to those which protected RGC-5 cells from complex I dysfunction in vitro." | 1.38 | Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. ( Anklin, C; Erb, M; Gueven, N; Heitz, FD; Pernet, V; Robay, D, 2012) |
| "In rats with cerebral ischemia, idebenone (10 mg/kg, i." | 1.28 | Effects of idebenone on metabolism of monoamines and cyclic AMP formation in rats. ( Kakihana, M; Nagai, Y; Nagaoka, A; Nagawa, Y; Narumi, S; Yamazaki, N, 1989) |
| "Pretreatment with idebenone (10 mg/kg, i." | 1.28 | Effects of idebenone on the levels of acetylcholine, choline, free fatty acids, and energy metabolites in the brains of rats with cerebral ischemia. ( Kakihana, M; Nagaoka, A; Yamazaki, N, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.71) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 8 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Blanco, LP | 1 |
| Pedersen, HL | 1 |
| Wang, X | 1 |
| Lightfoot, YL | 1 |
| Seto, N | 1 |
| Carmona-Rivera, C | 1 |
| Yu, ZX | 1 |
| Hoffmann, V | 1 |
| Yuen, PST | 1 |
| Kaplan, MJ | 1 |
| Shastri, S | 1 |
| Shinde, T | 1 |
| Sohal, SS | 1 |
| Gueven, N | 2 |
| Eri, R | 1 |
| Akpinar, E | 1 |
| Kutlu, Z | 1 |
| Kose, D | 1 |
| Aydin, P | 1 |
| Tavaci, T | 1 |
| Bayraktutan, Z | 1 |
| Yuksel, TN | 1 |
| Yildirim, S | 1 |
| Eser, G | 1 |
| Dincer, B | 1 |
| Moore, E | 1 |
| Reynolds, JA | 1 |
| Davidson, A | 1 |
| Gallucci, S | 1 |
| Morel, L | 1 |
| Rao, DA | 1 |
| Young, HA | 1 |
| Putterman, C | 1 |
| Huang, Y | 1 |
| Ma, M | 1 |
| Zhu, X | 1 |
| Li, M | 1 |
| Guo, M | 1 |
| Liu, P | 1 |
| He, Z | 1 |
| Fu, Q | 1 |
| Jiang, JX | 1 |
| Tomilov, A | 1 |
| Montgomery, C | 1 |
| Hui, CK | 1 |
| Török, NJ | 1 |
| Cortopassi, G | 1 |
| Wang, Y | 1 |
| Hu, LF | 1 |
| Cui, PF | 1 |
| Qi, LY | 1 |
| Xing, L | 1 |
| Jiang, HL | 1 |
| Kleiner, G | 1 |
| Barca, E | 1 |
| Ziosi, M | 1 |
| Emmanuele, V | 1 |
| Xu, Y | 1 |
| Hidalgo-Gutierrez, A | 1 |
| Qiao, C | 1 |
| Tadesse, S | 1 |
| Area-Gomez, E | 1 |
| Lopez, LC | 1 |
| Quinzii, CM | 1 |
| Soriano, S | 1 |
| Llorens, JV | 1 |
| Blanco-Sobero, L | 1 |
| Gutiérrez, L | 1 |
| Calap-Quintana, P | 1 |
| Morales, MP | 1 |
| Moltó, MD | 1 |
| Martínez-Sebastián, MJ | 1 |
| Iyer, S | 1 |
| Fiebiger, SM | 1 |
| Bros, H | 1 |
| Grobosch, T | 1 |
| Janssen, A | 1 |
| Chanvillard, C | 1 |
| Paul, F | 1 |
| Dörr, J | 1 |
| Millward, JM | 1 |
| Infante-Duarte, C | 1 |
| Tricoire, H | 1 |
| Palandri, A | 1 |
| Bourdais, A | 1 |
| Camadro, JM | 1 |
| Monnier, V | 1 |
| Sun, YN | 1 |
| Liu, LB | 1 |
| Xue, YX | 1 |
| Wang, P | 1 |
| Llewellyn, KJ | 1 |
| Nalbandian, A | 1 |
| Gomez, A | 1 |
| Wei, D | 1 |
| Walker, N | 1 |
| Kimonis, VE | 1 |
| Smith, TG | 1 |
| Seto, S | 1 |
| Ganne, P | 1 |
| Votruba, M | 1 |
| Lauro, F | 1 |
| Ilari, S | 1 |
| Giancotti, LA | 1 |
| Ventura, CA | 1 |
| Morabito, C | 1 |
| Gliozzi, M | 1 |
| Malafoglia, V | 1 |
| Palma, E | 1 |
| Paolino, D | 1 |
| Mollace, V | 1 |
| Muscoli, C | 1 |
| Abdel Baky, NA | 1 |
| Zaidi, ZF | 2 |
| Fatani, AJ | 1 |
| Sayed-Ahmed, MM | 1 |
| Yaqub, H | 1 |
| Rauchová, H | 1 |
| Vokurková, M | 1 |
| Drahota, Z | 1 |
| Heitz, FD | 1 |
| Erb, M | 1 |
| Anklin, C | 1 |
| Robay, D | 1 |
| Pernet, V | 1 |
| Ali, SA | 1 |
| Aly, HF | 1 |
| Faddah, LM | 1 |
| Seznec, H | 1 |
| Simon, D | 1 |
| Monassier, L | 1 |
| Criqui-Filipe, P | 1 |
| Gansmuller, A | 1 |
| Rustin, P | 1 |
| Koenig, M | 1 |
| Puccio, H | 1 |
| Cooper, JM | 1 |
| Schapira, AH | 1 |
| Amano, M | 1 |
| Goto, A | 1 |
| Takahashi, N | 1 |
| Hasegawa, T | 1 |
| Nabeshima, T | 1 |
| Wieland, E | 1 |
| Oellerich, M | 1 |
| Braun, F | 1 |
| Schtüz, E | 1 |
| Nagai, Y | 1 |
| Narumi, S | 1 |
| Kakihana, M | 3 |
| Yamazaki, N | 2 |
| Nagaoka, A | 3 |
| Nagawa, Y | 1 |
| Suno, M | 1 |
| Shibota, M | 1 |
2 reviews available for idebenone and Disease Models, Animal
| Article | Year |
|---|---|
Novel therapeutic approaches for Leber's hereditary optic neuropathy.
Topics: Animals; Antioxidants; Dietary Supplements; Disease Models, Animal; DNA-Binding Proteins; DNA, Mitoc | 2013 |
Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.
Topics: Animals; Ataxia; Benzoquinones; Coenzymes; Disease Models, Animal; Friedreich Ataxia; Humans; Iron; | 2007 |
26 other studies available for idebenone and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone.
Topics: Animals; Antioxidants; Disease Models, Animal; Extracellular Traps; Inflammation; Interleukin-17; In | 2020 |
Idebenone Protects against Acute Murine Colitis via Antioxidant and Anti-Inflammatory Mechanisms.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antioxidants; Colitis; Dextran Sulfate; Dis | 2020 |
Protective Effects of Idebenone against Sepsis Induced Acute Lung Damage.
Topics: Animals; Disease Models, Animal; Lung; Male; Oxidative Stress; Rats; Rats, Wistar; Sepsis; Ubiquinon | 2022 |
Promise and complexity of lupus mouse models.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Congresses as Topic; Disease Models, Animal; Drug | 2021 |
Effectiveness of idebenone nanorod formulations in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Humans; Mice; Mice, Trans | 2021 |
Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Choline Deficiency; Diet; Disease Models | 2021 |
Pathologically Responsive Mitochondrial Gene Therapy in an Allotopic Expression-Independent Manner Cures Leber's Hereditary Optic Neuropathy.
Topics: Animals; Disease Models, Animal; DNA; DNA, Mitochondrial; Electron Transport Complex I; Fluorescent | 2021 |
CoQ
Topics: Alkyl and Aryl Transferases; Animals; Antioxidants; Ataxia; Disease Models, Animal; HeLa Cells; Huma | 2018 |
Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
Topics: Aconitate Hydratase; Animals; Antioxidants; Deferiprone; Disease Models, Animal; Drosophila; Frataxi | 2013 |
The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse.
Topics: Animals; Antioxidants; Chronic Disease; Disease Models, Animal; Encephalomyelitis, Autoimmune, Exper | 2013 |
Methylene blue rescues heart defects in a Drosophila model of Friedreich's ataxia.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; D | 2014 |
Effects of insulin combined with idebenone on blood-brain barrier permeability in diabetic rats.
Topics: Animals; Antioxidants; Blood-Brain Barrier; Capillary Permeability; Diabetes Mellitus, Experimental; | 2015 |
Administration of CoQ10 analogue ameliorates dysfunction of the mitochondrial respiratory chain in a mouse model of Angelman syndrome.
Topics: Angelman Syndrome; Animals; Antioxidants; Cerebellum; Disease Models, Animal; Electron Transport; Hi | 2015 |
A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function.
Topics: Animals; Antioxidants; Blotting, Western; Dendrites; Disease Models, Animal; Female; GTP Phosphohydr | 2016 |
Pharmacological effect of a new idebenone formulation in a model of carrageenan-induced inflammatory pain.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Analgesics; Animals; Anti-Inflammatory Agents; Antioxidants; Carr | 2016 |
Nitric oxide pros and cons: The role of L-arginine, a nitric oxide precursor, and idebenone, a coenzyme-Q analogue in ameliorating cerebral hypoxia in rat.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Arginine; Brain; Catalase; Creatine Kinase; Disease M | 2010 |
Idebenone-induced recovery of glycerol-3-phosphate and succinate oxidation inhibited by digitonin.
Topics: Animals; Cytochromes c; Digitonin; Disease Models, Animal; Dose-Response Relationship, Drug; Glycero | 2012 |
Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy.
Topics: Administration, Oral; Animals; Antioxidants; Cell Line; Cell Survival; Disease Models, Animal; Drug | 2012 |
Dietary supplementation of some antioxidants against hypoxia.
Topics: Animals; Antioxidants; Arginine; Chemical and Drug Induced Liver Injury; Cytoprotection; Dietary Sup | 2012 |
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Topics: Animals; Benzoquinones; Cardiomyopathy, Dilated; Disease Models, Animal; Electrocardiography; Fratax | 2004 |
Effects of BMY-21502 on anoxia in mice.
Topics: Animals; Atmospheric Pressure; Benzoquinones; Brain Ischemia; Disease Models, Animal; Hypoxia, Brain | 1993 |
c-fos and c-jun mRNA expression in a pig liver model of ischemia/reperfusion: effect of extended cold storage and the antioxidant idebenone.
Topics: Animals; Antioxidants; Benzoquinones; Cold Temperature; Disease Models, Animal; Female; Gene Express | 2000 |
Effects of idebenone on metabolism of monoamines and cyclic AMP formation in rats.
Topics: Animals; Benzoquinones; Biogenic Monoamines; Brain; Brain Ischemia; Cyclic AMP; Disease Models, Anim | 1989 |
Effects of idebenone on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia.
Topics: Animals; Benzoquinones; Brain; Brain Ischemia; Cerebrovascular Circulation; Disease Models, Animal; | 1989 |
Effects of idebenone on the levels of acetylcholine, choline, free fatty acids, and energy metabolites in the brains of rats with cerebral ischemia.
Topics: Acetylcholine; Animals; Benzoquinones; Brain; Brain Ischemia; Choline; Disease Models, Animal; Energ | 1989 |